BACKGROUND: A consensus for which patients with thin melanomas (≤1 mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. METHODS: Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. RESULTS: Median age was 55 years, and 53% of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1%) of 271 cases; 8.4% of melanomas ≥0.76 mm were SLN positive with 5% of T1a melanomas ≥0.76 mm and 13% of T1b melanomas ≥0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas <0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate ≥1/mm(2) significantly correlated with nodal disease (p < 0.05) and ulceration correlated with SLN metastases (p < 0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLN patients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p < 0.01). CONCLUSIONS: SLN metastases were seen in 8.4% of thin melanomas ≥0.76 mm, including 5% of T1a melanomas ≥0.76 mm. We believe these rates are sufficient to justify consideration of SLNB in these patients, while the indications for SLNB in melanomas <0.76 mm remain to be defined.
BACKGROUND: A consensus for which patients with thin melanomas (≤1 mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. METHODS: Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. RESULTS: Median age was 55 years, and 53% of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1%) of 271 cases; 8.4% of melanomas ≥0.76 mm were SLN positive with 5% of T1a melanomas ≥0.76 mm and 13% of T1b melanomas ≥0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas <0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate ≥1/mm(2) significantly correlated with nodal disease (p < 0.05) and ulceration correlated with SLN metastases (p < 0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLNpatients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p < 0.01). CONCLUSIONS:SLN metastases were seen in 8.4% of thin melanomas ≥0.76 mm, including 5% of T1a melanomas ≥0.76 mm. We believe these rates are sufficient to justify consideration of SLNB in these patients, while the indications for SLNB in melanomas <0.76 mm remain to be defined.
Authors: Vernon K Sondak; Jeremy M G Taylor; Michael S Sabel; Yue Wang; Lori Lowe; Amelia C Grover; Alfred E Chang; Alan M Yahanda; James Moon; Timothy M Johnson Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: Julio Vaquerano; William G Kraybill; Deborah L Driscoll; Richard Cheney; John M Kane Journal: Ann Surg Oncol Date: 2006-01-19 Impact factor: 5.344
Authors: Christopher A Puleo; Jane L Messina; Adam I Riker; L Frank Glass; Christopher Nelson; C Wayne Cruse; Timothy M Johnson; Vernon K Sondak Journal: Cancer Control Date: 2005-10 Impact factor: 3.302
Authors: Susan B Kesmodel; Giorgos C Karakousis; Jeffrey D Botbyl; Robert J Canter; Robert T Lewis; Peter M Wahl; Kyla P Terhune; Abass Alavi; David E Elder; Michael E Ming; DuPont Guerry; Phyllis A Gimotty; Douglas L Fraker; Brian J Czerniecki; Francis R Spitz Journal: Ann Surg Oncol Date: 2005-04-19 Impact factor: 5.344
Authors: Karyn B Stitzenberg; Pamela A Groben; Stacey L Stern; Nancy E Thomas; Thomas A Hensing; Leah B Sansbury; David W Ollila Journal: Ann Surg Oncol Date: 2004-09-20 Impact factor: 5.344
Authors: Matthew F Kalady; Rebekah R White; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan Journal: Ir J Med Sci Date: 2014-11-01 Impact factor: 1.568
Authors: Sumeet Thareja; Jonathan S Zager; Divya Sadhwani; Shalini Thareja; Ren Chen; Suroosh Marzban; Drazen M Jukic; Lewis F Glass; Jane Messina Journal: Am J Dermatopathol Date: 2014-01 Impact factor: 1.533
Authors: Edmund K Bartlett; Phyllis A Gimotty; Andrew J Sinnamon; Heather Wachtel; Robert E Roses; Lynn Schuchter; Xiaowei Xu; David E Elder; Michael Ming; Rosalie Elenitsas; DuPont Guerry; Rachel R Kelz; Brian J Czerniecki; Douglas L Fraker; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2013-10-12 Impact factor: 5.344
Authors: K M Joyce; N M McInerney; R P Piggott; F Martin; D M Jones; A J Hussey; M J Kerin; J L Kelly; P J Regan Journal: Ir J Med Sci Date: 2017-01-28 Impact factor: 1.568
Authors: James M Chang; Heidi E Kosiorek; Amylou C Dueck; Stanley P L Leong; John T Vetto; Richard L White; Eli Avisar; Vernon K Sondak; Jane L Messina; Jonathan S Zager; Carlos Garberoglio; Mohammed Kashani-Sabet; Barbara A Pockaj Journal: Am J Surg Date: 2017-12-14 Impact factor: 2.565
Authors: Alexander Meves; Ekaterina Nikolova; Joel B Heim; Edwin J Squirewell; Mark A Cappel; Mark R Pittelkow; Clark C Otley; Nille Behrendt; Ditte M Saunte; Jorgen Lock-Andersen; Louis A Schenck; Amy L Weaver; Vera J Suman Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544